**Title:** Don’t Stick with the STATUS Quo: Management of Super Refractory Status Epilepticus

**Presenter:**  Madeline Mitchell, PharmD

PGY-2 Critical Care Pharmacy Resident

UPMC Presbyterian

**Date:** 08/24/2022

**Learning Objectives:**

1. Define status epilepticus types and initial management strategies
2. Discuss literature regarding treatment strategies in super refractory status epilepticus (SRSE)
3. Recognize important patient factors affecting SRSE management

**Abstract**

Super refractory status epilepticus (SRSE) is a rare disease state affecting only about 10% of all patients who develop status epilepticus. However, SRSE carries a high mortality rate ranging between 30-50% of affected patients. Seizure control is essential to prevent long-term neurological damage and functional deficits. Societal guidelines provide robust recommendations for initial management strategies of SE up to 40 minutes of seizure duration. However, after the addition of an anesthetic agent, guidance for treatment wanes. Therefore, controversy exists regarding the management of patients who continue to seize despite these recommended initial therapies. Available literature has largely focused on antiseizure and anesthetic medications to provide seizure control in these SRSE patients. This presentation will outline the efficacy, safety and patient-specific advantages and disadvantages for the use of propofol, midazolam, ketamine, and pentobarbital in SRSE patients.

**References**

1. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, Laroche SM, Riviello JJ Jr, Shutter L, Sperling MR, Treiman DM, Vespa PM; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012 Aug;17(1):3-23. doi: 10.1007/s12028-012-9695-z. PMID: 22528274.
2. Alolayan YS, McKinley K, Bhatia R, Alkhachroum A. Review and Updates on the Treatment of Refractory and Super Refractory Status Epilepticus. J Clin Med. 2021 Jul 7;10(14):3028. doi: 10.3390/jcm10143028. PMID: 34300194; PMCID: PMC8304618.
3. Poblete R, Sung G. Status Epilepticus and Beyond: A Clinical Review of Status Epilepticus and an Update on Current Management Strategies in Super-refractory Status Epilepticus. Korean J Crit Care Med. 2017 May;32(2):89-105. doi: 10.4266/kjccm.2017.00252. Epub 2017 May 31. PMID: 31723624; PMCID: PMC6786704.
4. Fang YT, Lee TL, Tu YH, Lin SH, Chien ME, Huang CW, Hsu KS, Wu YJ. Factors associated with mortality in patients with super-refractory status epilepticus. Sci Rep. 2022 Jun 11;12(1):9670. doi: 10.1038/s41598-022-13726-9. PMID: 35690663; PMCID: PMC9188563.
5. Boggs JG. Mortality Associated with Status Epilepticus. Epilepsy Curr. 2004 Jan;4(1):25-27. doi: 10.1111/j.1535-7597.2004.04110.x. PMID: 15346141; PMCID: PMC324580.
6. Madžar D, Knappe RU, Reindl C, Giede-Jeppe A, Sprügel MI, Beuscher V, Gollwitzer S, Hamer HM, Huttner HB. Factors associated with occurrence and outcome of super-refractory status epilepticus. Seizure. 2017 Nov;52:53-59. doi: 10.1016/j.seizure.2017.09.003. Epub 2017 Sep 9. PMID: 28963934.
7. Walker MC. Pathophysiology of status epilepticus. Neurosci Lett. 2018 Feb 22;667:84-91. doi: 10.1016/j.neulet.2016.12.044. Epub 2016 Dec 20. PMID: 28011391.
8. Goyal MK, Chakravarthi S, Modi M, Bhalla A, Lal V. Status epilepticus severity score (STESS): A useful tool to predict outcome of status epilepticus. Clin Neurol Neurosurg. 2015 Dec;139:96-9. doi: 10.1016/j.clineuro.2015.09.010. Epub 2015 Sep 15. PMID: 26409183.
9. Kapur J, Elm J, Chamberlain J, et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. *N Engl J Med.* 2019; 381:2103-13.
10. Meierkord H, Boon P, Engelsen B, Göcke K, Shorvon S, Tinuper P, Holtkamp M; European Federation of Neurological Societies. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010 Mar;17(3):348-55. doi: 10.1111/j.1468-1331.2009.02917.x. Epub 2009 Dec 30. PMID: 20050893.
11. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016 Jan-Feb;16(1):48-61. doi: 10.5698/1535-7597-16.1.48. PMID: 26900382; PMCID: PMC4749120.
12. Alolayan YS, McKinley K, Bhatia R, Alkhachroum A. Review and Updates on the Treatment of Refractory and Super Refractory Status Epilepticus. J Clin Med. 2021 Jul 7;10(14):3028. doi: 10.3390/jcm10143028. PMID: 34300194; PMCID: PMC8304618.
13. Vossler DG, Bainbridge JL, Boggs JG, Novotny EJ, Loddenkemper T, Faught E, Amengual-Gual M, Fischer SN, Gloss DS, Olson DM, Towne AR, Naritoku D, Welty TE. Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee. Epilepsy Curr. 2020 Sep;20(5):245-264. doi: 10.1177/1535759720928269. Epub 2020 Aug 21. PMID: 32822230; PMCID: PMC7576920.
14. Matthews E, Alkhachroum A, Massad N, Letchinger R, Doyle K, Claassen J, Thakur KT. New-onset super-refractory status epilepticus: A case series of 26 patients. Neurology. 2020 Oct 20;95(16):e2280-e2285. doi: 10.1212/WNL.0000000000010787. Epub 2020 Sep 17. PMID: 32943479; PMCID: PMC7713780.
15. Parviainen I, Uusaro A, Kälviäinen R, Mervaala E, Ruokonen E. Propofol in the treatment of refractory status epilepticus. Intensive Care Med. 2006 Jul;32(7):1075-9. doi: 10.1007/s00134-006-0154-1. Epub 2006 May 6. PMID: 16791671.
16. Mike, LA. Propofol related infusion syndrome. Pract Gastroenterol. 2010; 81: 16-24.
17. 21.Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: An 11-year clinical experience. Crit Care Med. 2009;37:3024–30.
18. Alkhachroum A., Der-Nigoghossian C., Mathews E., Massad N., Letchinger R., Doyle K., Chiu W.-T., Kromm J., Rubinos C., Velazquez A., et al. Ketamine to treat super-refractory status epilepticus. Neurology. 2020;95:e2286–e2294. doi: 10.1212/WNL.0000000000010611
19. Caranzano L, Novy J, Rossetti AO. Ketamine in adult super-refractory status epilepticus: Efficacy analysis on a prospective registry. Acta Neurol Scand. 2022 Jun;145(6):737-742. doi: 10.1111/ane.13610. Epub 2022 Mar 11. PMID: 35274736.
20. Pugin D., Foreman B., De Marchis G.M., Fernandez A., Schmidt J.M., Czeisler B.M., Mayer S.A., Agarwal S., Lesch C., Lantigua H., et al. Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: A cohort study. Crit. Care. 2014;18:R103. doi: 10.1186/cc13883.
21. Koh S, Kim TJ, Lim TS, Lee JS, Kim BG, Park SA, Huh K, Choi JY. Pentobarbital coma therapy for super-refractory status epilepticus and in-hospital mortality: an observational study. Epileptic Disord. 2021 Dec 1;23(6):833-842. doi: 10.1684/epd.2021.1333. PMID: 34642129.
22. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012 Aug;135(Pt 8):2314-28. doi: 10.1093/brain/aws091. Epub 2012 May 9. Erratum in: Brain. 2013 Jul;136(Pt 7):2326. PMID: 22577217.
23. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002 Feb;43(2):146-53. doi: 10.1046/j.1528-1157.2002.28501.x. PMID: 11903460.
24. Masapu D, Gopala Krishna KN, Sanjib S, Chakrabarti D, Mundlamuri RC, Manohar N, Mariamma P, Satishchandra P, Umamaheswara Rao GS. A Comparative Study of Midazolam and Target-Controlled Propofol Infusion in the Treatment of Refractory Status Epilepticus. Indian J Crit Care Med. 2018 Jun;22(6):441-448. doi: 10.4103/ijccm.IJCCM\_327\_17. PMID: 29962746; PMCID: PMC6020637.
25. Rossetti AO, Milligan TA, Vulliémoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2011 Feb;14(1):4-10. doi: 10.1007/s12028-010-9445-z. PMID: 20878265.

**Audience Response Questions**

1. CL is a 25 yo F with witnessed generalized convulsive seizure. She received 4mg lorazepam IV x1, a loading dose of levetiracetam, and an anesthetic agent is started. It has been 24h and CL continues to seize. What stage of SE is she in?
	1. Status epilepticus
	2. Refractory SE
	3. Super refractory SE
	4. Super duper refractory SE
2. MT has been diagnosed with SRSE. Propofol has been started and the attending physician asks you when MT is at higher risk of developing PRIS. How do you respond?
	1. After 24 hours of starting propofol
	2. After 48 hours of starting propofol
	3. After 72 hours of starting propofol
	4. No time is associated with PRIS development
3. SG was diagnosed with SRSE 9 days ago. She weighs 70 kg. Her ICU course has been complex, and she remains on epinephrine 21 mcg/min and norepinephrine 63 mcg/min. The resident recommends starting pentobarbital with an aggressive loading dose of 14 mg/kg. How do you respond?
	1. Agree, SG needs control of her SRSE
	2. Agree, pentobarbital has limited effect on hemodynamics
	3. Disagree, pentobarbital is not recommended in non-obese patients
	4. Disagree, pentobarbital could cause hemodynamic compromise